Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.





May 12, 2022

Company Takara Bio Inc. (Prime Market TSE, code: 4974)

Headquarters Nojihigashi 7-4-38, Kusatsu, Shiga, Japan

Representative Koichi Nakao, President & CEO

Contact Takuya Kakemi, Executive Officer, Head of

Corporate Management Division

Telephone (+81)77-565-6970

Website https://www.takara-bio.co.jp/

Notice of Dividends of Surplus

Takara Bio Inc. announced the declaration of the following dividend of retained earnings with a record date of March 31, 2022 at the Board of Directors meeting on May 12, 2022. This matter will be resolved at the Annual General Meeting of Shareholders to be held on June 24, 2022.

1. Details of dividends

| | Determined amount | Most recent dividend forecast (Announced on February. 10, 2022) | Results for the previous fiscal year (Year ended March 31, 2021) |
|-----------------------|-------------------|---|--|
| Record date | March 31, 2022 | March 31, 2022 | March 31, 2021 |
| Dividend per share | ¥33.00 | ¥30.00 | ¥16.00 |
| Total dividend amount | ¥3,973 million | - | ¥1,926 million |
| Effective date | June 27, 2022 | - June 25, 2021 | |
| Dividend source | Retained earnings | - | Retained earnings |

2. Reason

We consider returning profits to shareholders to be an important management issue, while paying attention to enhancing internal reserves in order to actively implement R&D activities in both Bioindustry business and Gene therapy business. Our basic policy is to return profits to shareholders based on a comprehensive consideration of our operating results and financial position. Specifically, the Company's policy is to pay dividends from retained earnings of approximately 20% of the estimated net income, which is calculated without taking into account extraordinary gains and losses in the consolidated financial statements.

Based on this policy, we revised its fiscal year-end dividend for the year ended March 31, 2022 to \(\frac{2}{3}3.00\), an increase of \(\frac{2}{3}.00\) from the previous forecast of \(\frac{2}{3}0.00\) per share announced on February 10, 2022.

(Reference)

| | Dividends per share | | |
|--------------------------------------|--------------------------------|----------|--------|
| Record Date | End of 2 nd quarter | Year-end | Total |
| Actual results | ¥0.00 | ¥33.00 | ¥33.00 |
| Results for the previous fiscal year | ¥0.00 | ¥16.00 | ¥16.00 |
| (Year ended March 31, 2021) | | | |

Forward-Looking Statements

Statements contained in these materials with respect to the Company's current plans, forecasts, strategies and beliefs that are not historical facts are forward-looking statements about the further performance of the Company and its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in light of information currently available to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.